Better understanding of the ADME-Tox properties of potential drug candidates is an integral part of the pharmaceutical industry’s current strategy to reduce the attrition rate in bringing new drugs to the market.
Aureus’ ADME/DDI and hERG knowledge databases contain detailed data including metabolism, inhibition, drug-drug interactions and pharmacokinetics which can help assess the safety of a potential pharmaceutical candidate.
"Aureus Pharma’s knowledge databases on ADME and hERG provide Siena Biotech researchers access to important data to assess ADME properties early in the drug discovery process and complement our in-house knowledge-based drug design platform," commented Siena Biotech’s Dr. Graeme M. Robertson, Vice President Therapeutic Research.
"We are very pleased that Siena Biotech has chosen Aureus Pharma's solutions," said Dr. Andre Michel, CEO of Aureus Pharma.
"Having access to the data in our ADME & hERG knowledge databases allows scientists to save valuable research time by using this prior knowledge and improve prioritization in drug discovery process."